# Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines

> **NCT04622254** · PHASE3 · COMPLETED · sponsor: **Merz North America, Inc.** · enrollment: 368 (actual)

## Conditions studied

- Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

## Interventions

- **DRUG:** NT 201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04622254
- **Lead sponsor:** Merz North America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-12
- **Primary completion:** 2021-06-16
- **Final completion:** 2022-07-08
- **Target enrollment:** 368 (ACTUAL)
- **Last updated:** 2024-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04622254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04622254, "Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04622254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*